The global Anti-Obesity Drug Market is projected to reach USD 82.55 Bn by 2032, with a CAGR of 18.01% from 2025. Factors driving growth include rising obesity rates, innovative drug formulations, and improved healthcare infrastructure in emerging economies.

Key takeaways include a 18% CAGR in demand for anti-obesity drugs, with prescription drugs dominating the market. GLP-1 receptor agonists are expected to hold a market share of 22.1% by 2025, while North America is set to capture 38.3% of the global market share.

Factors fueling market growth include the increasing prevalence of obesity and related chronic conditions like diabetes. By 2030, over 1 billion people are expected to be living with obesity, driving demand for anti-obesity drugs.

Despite positive outlook, high treatment costs and competition from non-pharmacological approaches could limit market growth. Expensive prescription drugs and growing popularity of alternative weight loss methods may hinder overall demand for anti-obesity drugs.

Rising health awareness and the focus on wellness are unlocking growth opportunities in the market. Digital health programs and personalized treatment plans that include prescription drugs are contributing to market expansion.

Emerging trends in the anti-obesity drug market include the development of GLP-1 receptor agonists like Mounjaro and Wegovy, and the expansion into lucrative markets like Asia Pacific. Combination therapies and the development of newer, more effective agents are also driving market growth.

Recent developments in the market include the launch of new weight-loss drugs by leading pharmaceutical companies and acquisitions to tackle the rising burden of obesity. Market segmentation includes drug type, drug class, route of administration, and regional insights across different geographies.

Read more at GlobeNewswire: Anti-Obesity Drug Market to Reach USD 82.55 Billion in